b'<?xml version="1.0" ?>\n<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">\n<PubmedArticleSet>\n<PubmedArticle>\n    <MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM">\n        <PMID Version="1">30834826</PMID>\n        <DateCompleted>\n            <Year>2020</Year>\n            <Month>02</Month>\n            <Day>21</Day>\n        </DateCompleted>\n        <DateRevised>\n            <Year>2020</Year>\n            <Month>02</Month>\n            <Day>21</Day>\n        </DateRevised>\n        <Article PubModel="Print">\n            <Journal>\n                <ISSN IssnType="Electronic">1873-4286</ISSN>\n                <JournalIssue CitedMedium="Internet">\n                    <Volume>25</Volume>\n                    <Issue>7</Issue>\n                    <PubDate>\n                        <Year>2019</Year>\n                    </PubDate>\n                </JournalIssue>\n                <Title>Current pharmaceutical design</Title>\n                <ISOAbbreviation>Curr. Pharm. Des.</ISOAbbreviation>\n            </Journal>\n            <ArticleTitle>Molecular Basis of Modulating Adenosine Receptors Activities.</ArticleTitle>\n            <Pagination>\n                <MedlinePgn>817-831</MedlinePgn>\n            </Pagination>\n            <ELocationID EIdType="doi" ValidYN="Y">10.2174/1381612825666190304122624</ELocationID>\n            <Abstract>\n                <AbstractText>Modulating cellular processes through extracellular chemical stimuli is medicinally an attractive approach to control disease conditions. GPCRs are the most important group of transmembranal receptors that produce different patterns of activations using intracellular mediators (such as G-proteins and Beta-arrestins). Adenosine receptors (ARs) belong to GPCR class and are divided into A1AR, A2AAR, A2BAR and A3AR. ARs control different physiological activities thus considered valuable target to control neural, heart, inflammatory and other metabolic disorders. Targeting ARs using small molecules essentially works by binding orthosteric and/or allosteric sites of the receptors. Although targeting orthosteric site is considered typical to modulate receptor activity, allosteric sites provide better subtype selectivity, saturable modulation of activity and variable activation patterns. Each receptor exists in dynamical equilibrium between conformational ensembles. The equilibrium is affected by receptor interaction with other molecules. Changing the population of conformational ensembles of the receptor is the method by which orthosteric, allosteric and other cellular components control receptor signaling. Herein, the interactions of ARs with orthosteric, allosteric ligands as well as intracellular mediators are described. A quinary interaction model for the receptor is proposed and energy wells for major conformational ensembles are retrieved.</AbstractText>\n                <CopyrightInformation>Copyright\xc2\xa9 Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.</CopyrightInformation>\n            </Abstract>\n            <AuthorList CompleteYN="Y">\n                <Author ValidYN="Y">\n                    <LastName>Mahmod Al-Qattan</LastName>\n                    <ForeName>Mohammed Nooraldeen</ForeName>\n                    <Initials>MN</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>College of Pharmacy, University Of Jerash, Jerash, Jordan.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Mordi</LastName>\n                    <ForeName>Mohd Nizam</ForeName>\n                    <Initials>MN</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Centre For Drug Research, Universiti Sains Malaysia, 11800 Gelugor, Penang, Malaysia.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n            </AuthorList>\n            <Language>eng</Language>\n            <PublicationTypeList>\n                <PublicationType UI="D016428">Journal Article</PublicationType>\n                <PublicationType UI="D016454">Review</PublicationType>\n            </PublicationTypeList>\n        </Article>\n        <MedlineJournalInfo>\n            <Country>United Arab Emirates</Country>\n            <MedlineTA>Curr Pharm Des</MedlineTA>\n            <NlmUniqueID>9602487</NlmUniqueID>\n            <ISSNLinking>1381-6128</ISSNLinking>\n        </MedlineJournalInfo>\n        <ChemicalList>\n            <Chemical>\n                <RegistryNumber>0</RegistryNumber>\n                <NameOfSubstance UI="D008024">Ligands</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>0</RegistryNumber>\n                <NameOfSubstance UI="D018047">Receptors, Purinergic P1</NameOfSubstance>\n            </Chemical>\n        </ChemicalList>\n        <CitationSubset>IM</CitationSubset>\n        <MeshHeadingList>\n            <MeshHeading>\n                <DescriptorName UI="D000495" MajorTopicYN="N">Allosteric Site</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D017076" MajorTopicYN="Y">Computer-Aided Design</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D015195" MajorTopicYN="Y">Drug Design</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D008024" MajorTopicYN="N">Ligands</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D018047" MajorTopicYN="N">Receptors, Purinergic P1</DescriptorName>\n                <QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>\n            </MeshHeading>\n        </MeshHeadingList>\n        <KeywordList Owner="NOTNLM">\n            <Keyword MajorTopicYN="Y">Adenosine receptor</Keyword>\n            <Keyword MajorTopicYN="Y">GPCR</Keyword>\n            <Keyword MajorTopicYN="Y">allosteric ligands</Keyword>\n            <Keyword MajorTopicYN="Y">interaction model</Keyword>\n            <Keyword MajorTopicYN="Y">modulators</Keyword>\n            <Keyword MajorTopicYN="Y">orthosteric</Keyword>\n            <Keyword MajorTopicYN="Y">receptor conformations.</Keyword>\n        </KeywordList>\n    </MedlineCitation>\n    <PubmedData>\n        <History>\n            <PubMedPubDate PubStatus="received">\n                <Year>2019</Year>\n                <Month>02</Month>\n                <Day>02</Day>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="accepted">\n                <Year>2019</Year>\n                <Month>02</Month>\n                <Day>26</Day>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="pubmed">\n                <Year>2019</Year>\n                <Month>3</Month>\n                <Day>6</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="medline">\n                <Year>2020</Year>\n                <Month>2</Month>\n                <Day>23</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="entrez">\n                <Year>2019</Year>\n                <Month>3</Month>\n                <Day>6</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n        </History>\n        <PublicationStatus>ppublish</PublicationStatus>\n        <ArticleIdList>\n            <ArticleId IdType="pubmed">30834826</ArticleId>\n            <ArticleId IdType="pii">CPD-EPUB-97025</ArticleId>\n            <ArticleId IdType="doi">10.2174/1381612825666190304122624</ArticleId>\n        </ArticleIdList>\n    </PubmedData>\n</PubmedArticle>\n\n</PubmedArticleSet>'